Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

Claris confirms break-up with Pfizer

This article was originally published in Scrip

  • News

Executive Summary

Claris Lifesciences has confirmed that its supply agreement with Pfizer has been terminated and it will pursue selling products on its own in the US. Scrip had on 22 August reported that the alliance had been called off and that Pfizer had 'no current plans' to source 'any products' from Claris (scripintelligence.com 22 August 2012).

You may also be interested in...



Chiesi Files India Legal Action Against Cipla Over Respiratory Therapy Patent

The Italian firm has initiated legal proceedings in India against Cipla, alleging infringement of a patent for an inhalation therapy.

Novartis Sheds Vildagliptin Trademark In India Ahead Of Patent Expiry

Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.

Cipla's COO Steps Down

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

Table

View full table

Related Companies

Tags:
UsernamePublicRestriction

Register

SC018555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By